PriceTargets.com logo

Bionomics - BNOX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 835.75%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.96 As of 04/26/2024 01:34 PM ET
▼ -0.0045 (-0.47%)

This chart shows the closing price for BNOX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bionomics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BNOX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BNOX

Analyst Price Target is $9.00
▲ +835.75% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Bionomics in the last 3 months. The average price target is $9.00, with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 835.75% upside from the last price of $0.96.

This chart shows the closing price for BNOX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Bionomics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00Low
12/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$8.00Low
9/28/2023Maxim GroupBoost TargetBuy ➝ Buy$7.00 ➝ $10.00N/A
9/28/2023HC WainwrightUpgradeNeutral ➝ Buy$8.00N/A
6/16/2023Maxim GroupInitiated CoverageBuyLow
3/10/2023Cantor FitzgeraldLower Target$10.00 ➝ $8.00Low
3/10/2023Evercore ISIUpgradeIn-Line ➝ Outperform$6.00Low
3/9/2023HC WainwrightReiterated RatingNeutralLow
3/9/2023Loop CapitalBoost TargetBuy$10.00 ➝ $17.00Low
12/20/2022Evercore ISIReiterated RatingOutperform ➝ In-Line$17.00 ➝ $6.00Low
12/19/2022HC WainwrightDowngradeBuy ➝ NeutralLow
11/1/2022Loop CapitalInitiated CoverageBuy$23.00Low
5/16/2022Evercore ISIDowngradeOutperformLow
1/10/2022Berenberg BankInitiated CoverageBuy$21.00Medium
1/10/2022William BlairInitiated CoverageOutperformMedium
1/10/2022Cantor FitzgeraldInitiated CoverageOverweightMedium
1/10/2022HC WainwrightInitiated CoverageBuyMedium
1/10/2022Evercore ISIInitiated CoverageOutperform$17.00Medium
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Bionomics logo
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Read More

Today's Range

Now: $0.96
Low: $0.93
High: $1.00

50 Day Range

MA: $1.07
Low: $0.92
High: $1.25

52 Week Range

Now: $0.96
Low: $0.87
High: $6.41

Volume

30,434 shs

Average Volume

190,695 shs

Market Capitalization

$7.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Bionomics?

The following Wall Street research analysts have issued research reports on Bionomics in the last year: HC Wainwright, and Maxim Group.
View the latest analyst ratings for BNOX.

What is the current price target for Bionomics?

2 Wall Street analysts have set twelve-month price targets for Bionomics in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 835.7%. Maxim Group has the highest price target set, predicting BNOX will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for Bionomics in the next year.
View the latest price targets for BNOX.

What is the current consensus analyst rating for Bionomics?

Bionomics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BNOX will outperform the market and that investors should add to their positions of Bionomics.
View the latest ratings for BNOX.

What other companies compete with Bionomics?

Other companies that are similar to Bionomics include TFF Pharmaceuticals, Biofrontera, Chemomab Therapeutics, ASLAN Pharmaceuticals and Pasithea Therapeutics. Learn More about companies similar to Bionomics.

How do I contact Bionomics' investor relations team?

Bionomics' physical mailing address is 31 Dalgleish St, Thebarton, South Australia 5031. The company's listed phone number is 088-150-7400 and its investor relations email address is [email protected]. The official website for Bionomics is www.bionomics.com.au. Learn More about contacing Bionomics investor relations.